Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study

Overview of attention for article published in Frontiers in oncology, October 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 2 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,663 followers.

RT @FrontOncology: New research: Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pa…

17 Oct 2023

Reply Repost Favourite

New research: Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study: Background A survival benefit has been seen for both adjuvant nab-paclitaxel plus… https://t.co/Ue

17 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.